Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00001204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 270 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    Re-verified, no change to tracked fields

  2. Minor

    Eligibility criteria expanded, about 1 word

    Publications: details revised at 3 of 3 entries

    Show what changed: Eligibility criteria
    * INCLUSION CRITERIA: Fasting cholesterol greater than 500 mg/ [...]

  3. Minor

    48 amendments

    48 re-verifications since 2024-08-14, no change to tracked fields

    v221-v268

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Homozygous familial hypercholesterolemia is a rare inherited disease of metabolism. It occurs in less than 1 in 1 million people within the United States. Patients with the disease are typically children and young adults who develop heart disease early in life. Children less than age 5 years with this disease have suffered heart attacks and death. The normal process that removes cholesterol particles from the blood stream does not work in patients with this disease. It causes cholesterol to build-up in the arteries and leads to hardening of the arteries (atherosclerosis). The goal of this study is to detect and measure atherosclerosis in these patients before it becomes permanent and potentially life threatening. Patients with this disease can participate in this study. Researchers plan to evaluate patients with homozygous familial hypercholesterolemia using new and standard methods for detecting atherosclerosis. Researchers plan to use information gathered during this study to develop new, promising treatments such as liver transplantation and gene therapy.
Trial Details
NCT Number NCT00001204
Lead Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Conditions Homozygous Familial Hypercholesterolemic
Enrollment 73 participants
Start Date
Updated on ClinicalTrials.gov